Path to Public Series
Life Science IPO Exit Strategies: Planning to Execution
Event summary
Curious about the initial public offering (IPO) process? Join us for an insightful virtual discussion on key considerations and strategies, featuring industry leaders who will share their perspectives on navigating the IPO process, as well as reflections on lessons learned.
Topics include:
- Capital markets update
- IPO strategy overview
- Perspectives from industry-leading advisors
- Reflections from C-suite executives on lessons learned
Speakers
- Carlos Ramirez – Partner at Cooley
- Tasia Blazevich – Managing director and US life sciences IPO co-leader at Deloitte
- B.J. Spence – Partner and US life sciences IPO co-leader at Deloitte
- Stephen Feider – Chief financial officer at Beta Bionics
- John Haynor – Managing director at Solebury Capital
- Jun Yoon – Chief financial officer at Structure Therapeutics
For more information, please email Aimee Nguyen.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.